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Abstract Chronic opioid regulation of stimulatory receptor
activity was investigated in neuroblastomaUglioma (NG108-15)
hybrid cells stably transfected to express the human L2-
adrenoceptor (L2-AR). Expressed L2-ARs are functionally
coupled to G proteins and display ligand-independent signalling
activity, as demonstrated by the ability of an inverse agonist to
attenuate basal adenylyl cyclase (AC) activity. Despite the
relative increase in basal AC activity due to the development of
tolerance/dependence, chronic morphine treatment was found to
completely abolish spontaneous L2-AR activity by reducing basal
receptor/G protein precoupling. A similar chronic opioid effect
was observed in transiently transfected COS-7 cells. These
results indicate that during the state of opioid tolerance/
dependence basal levels of AC activity are no longer under the
control of spontaneously active stimulatory receptors. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic activation of inhibitory opioid receptors (OR) re-
sults in the development of tolerance and dependence. The
underlying cellular mechanisms are complex and involve
adaptations in OR-associated signal transduction pathways
[1,2]. Whereas the phenomenon of opioid tolerance is fre-
quently associated with desensitisation of OR activity, e.g.
by phosphorylation, internalisation or down-regulation of
the binding site [3,4], more down-stream adaptations are im-
plicated in the development of dependence [5]. These regula-
tory changes develop in response to persistent OR activation
and are thought to attenuate or counteract persistent inhibi-
tory signal transduction on post-receptor level [6^8].
One of the best-studied chronic opioid e¡ects on post-re-
ceptor level is sensitisation of adenylyl cyclase (AC), which is
characterised by a transient increase in cAMP production
after drug withdrawal [5,8,9]. Because the AC e¡ector system
is under dual control by both stimulatory and inhibitory re-
ceptors, we have recently proposed that the increase in AC
activity following chronic morphine treatment is due to an
increased activity of stimulatory receptor systems [8,10]. In-
deed, chronic opioid treatment was found to induce multiple
quantitative and qualitative adaptations at the level of stim-
ulatory PGE1 receptors and guanine nucleotide-binding pro-
teins (G proteins) in both neuroblastomaUglioma (NG108-
15) hybrid and neuroblastoma SH-SY5Y cells [8,10,11]. How-
ever, these studies also revealed that the increase in AC activ-
ity during the state of opioid tolerance/dependence is accom-
panied by a paradoxical reduction in the maximum binding
capacity for [3H]PGE1 [8,11,12]. Due to the lack of a suitable
antagonist radioligand for this receptor species, we were not
able to assign this observation to receptor uncoupling or to
real down-regulation. Thus, the aim of the present study was
to more closely investigate the role of stimulatory receptors in
the phenomenon of chronic opioid-induced sensitisation of
AC. For this, the human L2-adrenoceptor (L2-AR) was stably
expressed in NG108-15 cells and the functional properties of
this receptor were analysed by a variety of di¡erent ap-
proaches, including the use of an inverse agonist to evaluate
the extent of spontaneous receptor activity [13,14]. The data
obtained demonstrate that in stably transfected NG108-15
cells chronic morphine treatment has no e¡ect on overall
L2-AR abundance but substantially reduces the number of
spontaneously active, G protein-coupled receptors.
2. Materials and methods
2.1. Materials
[125I]Cyanopindolol (CYP; 2000 Ci/mmol), [5,6(n)-3H]prostaglan-
din E1 (PGE1, 47 Ci/mmol), and [125I]cAMP tracer (2000 Ci/mmol)
were from Amersham International. The inverse L2-AR agonist
( þ )-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methyl-ethyl)-
amino]-2-butanol hydrochloride (ICI-118,551), R(3)-isoproterenol
(+)-bitartrate, S(3)-propranolol hydrochloride, S(3)-timolol maleate,
and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Re-
search Biochemicals International. Anti-cAMP antibody was from
BioYeda, goat anti-rabbit peroxidase-conjugated IgG was from Prom-
ega. ATP, cAMP, and all other guanine nucleotides were obtained
from Calbiochem. Tissue culture reagents and geneticin (G418) were
from Gibco BRL Life Technologies. DOTAP transfection reagent was
from Boehringer (Mannheim), methotrexate, PGE1, indomethacin,
and all standard laboratory reagents were purchased from Sigma
Chemical Company.
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2.2. Methods
2.2.1. Cell culture, transfection, and chronic opioid treatment. Neuro-
blastomaUglioma (NG108-15) cells carrying endogenous N-ORs were
cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 5% (v/v) foetal bovine serum, 100 WM hypoxanthine,
1 WM aminopterin, 16 WM thymidine, 100 units/ml penicillin, and
100 Wg/ml streptomycin at 37‡C in 5% CO2. A stably L2-AR express-
ing cell clone (NGL20) was generated by co-transfection of the cells
with plasmids pBC-dhfr-L2AR and pSV2-neo using DOTAP trans-
fection reagent. After selection with neomycin (G418; 800 Wg/ml),
L2-AR levels were ampli¢ed by successive exposure to increasing con-
centrations of methotrexate (0.01, 0.03, and 0.1 WM) for 14 days each.
For experimentation, subcon£uent monolayers were rendered opioid
tolerant/dependent by chronic exposure to morphine (10 WM) for
3 days [8]. In each case, cells of an identical passage, which were
kept in the absence of the opioid, served as controls.
COS-7 cells were grown as described [15]. Cells (10-cm petri dish)
were transiently co-transfected with 3 Wg each of cDNA’s coding for
the rat W-OR, the human L2-AR, and the rabbit AC type V, all sub-
cloned into plasmid pcDNA3.1 (Invitrogen). The day after transfec-
tion, cells were trypsinised, distributed into two 24-well plates, and
cultured for another 2 days either in the absence of presence of 1 WM
morphine to induce tolerance/dependence.
2.2.2. Radioligand binding assays. These were performed on par-
ticulate membrane preparations obtained as described [12]. The ¢nal
membrane pellets were resuspended in the appropriate assay bu¡ers
(see below) and immediately used for experimentation. In case of
chronically morphine pre-treated cells, all binding assays were con-
ducted in the presence of 10 WM morphine in order to maintain
tolerance/dependence.
The total L2-AR number was determined from saturation binding
experiments using [125I]CYP (0.04^2 nM) as the radioligand [14]. Het-
erologous binding experiments were performed with [125I]CYP as the
tracer (0.08 nM) and either the L2-AR agonist isoproterenol, the com-
petitive antagonist propranolol or the inverse L2-AR agonist ICI-
118,551 as competitors. Binding reactions (200 Wl volume) contained
10^30 Wg of membrane protein in 20 mM Tris^HCl bu¡er, pH 7.4,
supplemented with 5 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic
acid, and 0.1 mg/ml BSA. Non-speci¢c binding was de¢ned in the
presence of 10 WM propranolol. Binding reactions were conducted
to equilibrium (90 min; 25‡C) before they were terminated by rapid
¢ltration through Whatman GF/B ¢lters. Saturation isotherms were
analysed by the method of Scatchard, yielding estimates for maximum
binding capacity (Bmax) and ligand a⁄nity (Kd). Competition binding
data were subjected to non-linear least-squares regression analysis
using a two-state model [14]. Ki values were calculated from IC50
values according to the equation of Cheng and Pruso¡ [16].
PGE1 receptors were measured using a single [3H]PGE1 tracer
(8 nM) concentration in the presence of 10 mM Tris^HCl bu¡er
(pH 7.4), containing 5 mM MgCl2, 100 mM NaCl, 100 WM indometh-
acin, and 10 mM benzamidine [12]. Binding reactions (200 Wl volume)
contained 300 Wg of membrane protein and were conducted for 90 min
at 25‡C. Non-speci¢c binding was assessed in the presence of 10 WM
PGE1. The fraction of functionally G protein-coupled PGE1 receptors
was determined in the presence of the stable guanine-nucleotide
GTPQS (100 WM). The total number of G protein-coupled receptors
was calculated according to the method of DeBlasi et al. [17] using a
Kd value of 2.9 nM for the high-a⁄nity binding site [12].
2.2.3. AC assays. Enzymatic activity of membrane-bound AC was
determined as described [10]. The assay system (100 Wl total volume)
contained 40 mM Tris^HCl, pH 7.4, 0.2 mM EGTA, 0.2 mM DTT,
100 mM NaCl, 10 mM MgCl2, 0.5 mM ATP, 5 Wg/ml phosphocrea-
tine, 5 IU/ml creatine phosphokinase, 10 WM GTP, 100 WM IBMX
and various ligands as indicated in the text and ¢gure legends. Reac-
tions were started by the addition of 10 Wg of membrane protein, kept
for 10 min at 32‡C, and were stopped with 500 Wl of ice-cold 10 mM
HCl.
Accumulation of cAMP in intact COS-7 cells was determined as
follows: cells grown in 24-well plates were washed three times with
1 ml/well of prewarmed sodium bicarbonate-free DMEM containing
20 mM HEPES (DMEH; pH 7.4), before reactions were started by
the addition of 0.25 ml/well of DMEH, supplemented with 1 mM
IBMX, 0.01% BSA, and the appropriate receptor ligands as indicated.
Chronically morphine (1 WM; 2 days) pre-treated cells were assayed in
the continued presence of morphine. Accumulation of cAMP was
allowed for 15 min at 37‡C and was terminated by the addition of
0.75 ml of ice-cold 50 mM HCl. The amount of cAMP generated was
determined in the supernatant fraction by radioimmunoassay [10].
2.2.4. Electrophoresis and Western blotting. Membrane proteins
(10 Wg/lane) prepared from NG108-15 wild-type and clonal NGL20
cells were solubilised in Laemmli loading bu¡er [18], resolved by SDS-
PAGE (10%; w/v), and transferred onto PVDF membranes (Immo-
bilon P; Millipore). The blots were probed with subtype-speci¢c anti-
G protein antibodies (anti-stimulatory G protein K-subunit (GsK) ;
anti-GL) as primary reagent [8] followed by incubation with a peroxi-
dase-conjugated goat anti-rabbit secondary antibody. Immunoreactiv-
ity was visualised using enhanced chemiluminescence (Amersham) and
quantitated by video densitometry (Herolab E.A.S.Y. RH-3 system).
3. Results and discussion
To investigate the role of stimulatory receptors in chronic
opioid-induced sensitisation of AC, the human L2-AR was
stably expressed in NG108-15 cells. Scatchard plot analysis
of [125I]CYP saturation binding data (Fig. 1A) revealed that
Fig. 1. Functional expression of the human L2-AR in neuroblasto-
maUglioma (NG108-15) hybrid cells. A: Saturation binding of
[125I]CYP to membranes from clonal NGL20 cells. The data shown
are representative for three similar experiments, done in triplicate.
Inset: Scatchard transformation of the data yielded estimates for
Bmax (1.032 þ 62 fmol/mg membrane protein) and Kd (87.6 þ 5 pM)
(mean values þ S.D.; n = 3). B: Heterologous displacement of
[125I]CYP tracer binding with increasing concentrations of isoproter-
enol. Membranes were assayed either in the absence or presence of
the stable guanine nucleotide GTPQS (100 WM). About 35.8 þ 9% of
the receptors show high-a⁄nity agonist binding with a KiH value of
3.6 þ 1.2 nM (mean value þ S.D. of n = 5 independent experiments)
according to a two-state model.
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the cell clone used in this study (NGL20) carries high levels of
the L2-ARs (Bmax = 1.032 þ 62 fmol/mg membrane protein;
Kd = 87.6 þ 5 pM; mean values þ S.D.; n = 3). Heterologous
displacement of [125I]CYP binding by the L2-AR agonist iso-
proterenol produced a biphasic competition curve with a pro-
portion of 35.8 þ 9% of high-a⁄nity receptors (KiH = 3.6 þ 1.2
nM; mean values þ S.D.; n = 5). Uncoupling of the receptors
from Gs in the presence of the stable guanine-nucleotide
GTPQS (100 WM) resulted in a complete loss of high-a⁄nity
agonist binding, yielding a monophasic competition curve
with a KiL value of 1.1 þ 0.3 WM (mean þ S.D.; n = 3) for the
low-a⁄nity receptor state (Fig. 1B). These results demonstrate
that expressed L2-ARs are functionally coupled to Gs.
According to current receptor theory, G protein-coupled
receptors exist in equilibrium between two conformations,
an inactive (R) and an active (R*) receptor state, that can
isomerise spontaneously in a native membrane environment
[13,14]. The active receptor state is able to productively inter-
act with its corresponding G proteins, initiating subsequent
signal transduction processes. As the absolute number of
spontaneously active receptor increases with higher receptor
levels [19], overexpression of L2-ARs in NGL20 cells was
found to signi¢cantly increase basal AC activity compared
to parental NG108-15 hybrid cells (50.1 þ 1.9 vs. 34.8 þ 2.7
pmol cAMP/mg/min; mean values þ S.E.M. of n = 12 and
three independent experiments, respectively; P6 0.001), con-
¢rming previous data [20].
Ligands acting on G protein-coupled receptors may be clas-
si¢ed either as agonist, neutral antagonist or inverse agonist,
depending on their e¡ect on the equilibrium between both
receptor states [21]. Receptor agonists stimulate signal trans-
duction processes by increasing the relative proportion of the
activated receptor state due to their higher a⁄nity for this
receptor conformation. Neutral antagonists have no e¡ect
on the equilibrium between both receptor states and act solely
in a competitive manner. In contrast, negative antagonists
(inverse agonists) stabilise the inactive receptor state and,
thus, are able to reduce the number or spontaneously active
receptors [13,21,22]. Therefore, we tested whether the increase
in basal AC activity due to L2-AR overexpression may be
reversed by an inverse agonist. As shown in Fig. 2A, inacti-
vation of L2-ARs by an inverse agonist (ICI-118,551, timolol ;
1 WM each) signi¢cantly inhibited basal AC activity by some
30%, reaching values comparable to those observed for
NG108-15 wild-type cells. Propranolol (1 WM) behaved as a
neutral antagonist in this cell system and blocked the inverse
agonist e¡ect. Acute activation of inhibitory N-ORs by mor-
phine (10 WM) attenuated basal AC activity to the same extent
as observed for inverse L2-AR agonists. Concomitant inacti-
vation of stimulatory L2-ARs as well as activation of inhib-
itory N-ORs failed to cooperatively inhibit AC activity. The
e¡ects of inverse L2-AR agonists as well as N-OR agonists on
basal AC activity emphasise the mechanism by which stimu-
latory and inhibitory GK subunits regulate enzymatic AC ac-
tivity. Whereas activated GsK is the principal stimulator of
enzymatic activity, inhibitory GK subunits represent secondary
regulators of AC that are only able to inhibit the stimulated
but not the unstimulated enzyme [23]. Thus, termination of
spontaneous GsK-mediated stimulation of AC activity by an
inverse L2-AR agonist might explain the failure of concomi-
tant activation of inhibitory N-ORs to further attenuate basal
AC activity.
The most important ¢nding of the present paper, however,
was that chronic morphine treatment (10 WM; 3 days) com-
pletely abolished the inhibitory e¡ect of ICI-118,551 on basal
AC activity (Fig. 2A). Similar results were obtained in tran-
siently L2-AR-transfected COS-7 cells co-expressing the rat W-
OR and the rabbit AC type V, indicating that the failure of
inverse L2-AR agonists to attenuate basal AC activity during
the state of opioid tolerance/dependence is not restricted to
clonal NGL20 cells but rather represents a more general
chronic opioid e¡ect (Fig. 2B).
There are two possibilities for how chronic morphine treat-
ment could block attenuation of basal AC activity by ICI-
Fig. 2. E¡ect of inverse L2-AR agonists on basal AC activity.
A: Membranes from naive or chronically morphine (10 WM; 3 days)
pre-treated NGL20 cells were prepared and AC activity was mea-
sured in the presence of the following ligands: morphine (Mor; 10
WM), ICI-118,551 (ICI; 1 WM), propranolol (Prop; 1 WM), and tim-
olol (Tim; 1 WM). Membranes from opioid tolerant/dependent cells
were assayed in the presence of morphine (10 WM). AC activity is
expressed as the amount of cAMP formed per min per mg of mem-
brane protein. The data are mean values þ S.E.M. of the number of
experiments indicated. B: COS-7 cells were transiently transfected
with cDNA’s encoding the L2-AR, W-OR, and AC type V, and regu-
lation of basal cAMP accumulation in naive and chronically mor-
phine pre-treated cells was analysed as above. The data shown are
mean values þ variation of a representative experiment performed in
quadruplicate determination. Two additional experiments yielded
qualitatively similar results. ***Signi¢cantly di¡erent, P6 0.001.
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118,551. First, there is still persistent inhibition of AC via
inhibitory GK subunits associated with the development of
tolerance which might obliterate the inverse L2-AR e¡ect [7]
and, second, chronic morphine treatment could reduce the
number of spontaneously active stimulatory receptors [20].
Because investigation of inverse L2-AR activity in membranes
from opioid tolerant/dependent cells is excluded in the ab-
sence of morphine due to the expression of AC supersensitiv-
ity [15], we tried to attack this issue by investigating whether
chronic morphine treatment could possibly attenuate sponta-
neous L2-AR activity. For this, the property of inverse ago-
nists to bind with high a⁄nity to the inactive receptor con-
formation was used to evaluate the fraction spontaneously
active receptors. In membranes of naive NGL20 cells, heter-
ologous [125I]CYP binding experiments using the inverse
L2-AR agonist ICI-118,551 as the competitor produced a bi-
phasic displacement curve with about 21.2 þ 3% of the recep-
tors showing low a⁄nity for the competitor (KiL = 32.8 þ 18
nM; mean þ S.D.; n = 4) (Fig. 3). Inactivation of spontaneous
receptor activity by receptor uncoupling (GTPQS; 100 WM)
yielded a monophasic displacement curve with high a⁄nity
for the inverse agonist (Ki = 1.1 þ 0.2 nM; mean þ S.D.;
n = 3). Chronic morphine treatment mimicked the GTPQS ef-
fect (Ki for ICI-118,551 = 1.2 þ 0.3 nM; mean þ S.D.; n = 4),
indicating that spontaneous L2-AR activity is reduced in
membranes from opioid tolerant/dependent NGL20 cells. Ad-
dition of morphine to membranes from naive cells had no
e¡ect on ICI-118,551 binding parameters (22.9 þ 7% low af-
¢nity receptors; KiL = 43.4 þ 21 nM; mean þ S.D.; n = 2).
These results con¢rm that inverse agonists indeed are able
to distinguish between active and inactive receptor forms,
and that they display reciprocal binding characteristics com-
pared to agonists [24,25]. Moreover, they also suggest that
chronic morphine treatment reduces the number of spontane-
ously active L2-ARs as observed after receptor uncoupling.
Comparable results were obtained when heterologous
[125I]CYP binding experiments were performed using the ago-
nist isoproterenol as a competitor (Table 1).
There are several possibilities by which chronic morphine
treatment could down-regulate spontaneous L2-AR activity.
In this respect, changes in receptor and G protein abundance
have been reported to a¡ect the equilibrium between the ac-
tive and the inactive receptor conformation [24^26]. Scatchard
Fig. 3. Chronic morphine treatment alters inverse L2-AR agonist
binding properties. Membranes from naive and chronically mor-
phine (10 WM; 3 days) pre-treated NGL20 cells were subjected to
heterologous binding experiments using [125I]CYP (0.08 nM) as the
tracer and increasing concentrations of the inverse L2-AR agonist
ICI-118,551 as competitor. In membranes from naive cells, ICI-
118,551 recognised two binding sites with the lower a⁄nity state
being sensitive to the stable guanine nucleotide GTPQS. Chronic
morphine pre-treatment completely abolished the low-a⁄nity bind-
ing site for ICI-118,551, leaving a single site with high-a⁄nity. Data
are mean values þ S.D. of four (naive, chronic morphine) and three
(GTPQS) separate experiments.
Table 1
Regulation of [125I]CYP binding by (3)-isoproterenol in NGL20 cells
Pre-treatment Addition (3)-Isoproterenol binding parameters
KH (nM) KL (WM) RH (%) RL (%) n
None ^ 3.6 þ 1.2 1.3 þ 0.3 32.1 þ 8 67.7 þ 6 5
GTPQS NA 1.1 þ 0.3 NA 99 þ 1 3
Morphine ^ 3.8 þ 1.6 1.4 þ 0.4 16.7 þ 5a 83.0 þ 5a 4
GTPQS NA 1.2 þ 0.2 NA 98 þ 2 3
A⁄nity states for isoproterenol were obtained from heterologous binding experiments using [125I]CYP as the tracer and 12 di¡erent concentra-
tions of the competitor. Ki values were calculated from IC50 values according to the method of Cheng and Pruso¡ [17]. KH and KL designate
Ki values of the high (H) and low (L) a⁄nity states. RH and RL designate proportion of receptor in high- and low-a⁄nity states. Data are ex-
pressed as means þ S.D. Numbers in parentheses indicate percentage reduction of high-a⁄nity L2-ARs by activation of PGE1 receptors. NA,
not applicable (one-site binding).
aSigni¢cantly di¡erent to controls, P6 0.001.
Fig. 4. E¡ect of L2-AR expression and chronic morphine treatment
on Gs levels. Membrane proteins (10 Wg) from NG108-15 wild-type
and stably L2-AR transfected NGL20 cells were resolved by 10%
(w/v) SDS-PAGE and immunoblotted for GsK and GL subunits as
described in Section 2. In NG108-15 cells, the C-terminal anti-GsK
antibody recognises a major form of GsK migrating with a molecu-
lar mass of V48 kDa, whereas the anti-GL antibody labels a band
at V35 kDa. Neither stable expression of the L2-AR nor chronic
morphine treatment (10 WM; 3 days) a¡ects G protein abundance.
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plot analysis of [125I]CYP saturation binding data failed to
detect quantitative changes for L2-ARs following chronic
morphine treatment (Bmax = 1.032 þ 62 versus 989 þ 74 fmol/
mg membrane protein for naive and chronically morphine-
treated cells, respectively; mean values þ S.D.; n = 3). Like-
wise, the amount of GsK and GL subunits remained un-
changed in membranes from opioid tolerant/dependent cells.
As shown in Fig. 4, wild-type NG108-15 cells contain a prom-
inent GsK isoform with an apparent molecular weight of V48
kDa. Overexpression of L2-ARs in NGL20 cells as well as
chronic morphine treatment had no e¡ect on relative GsK
and GL concentrations. Thus, the loss of spontaneously active
L2-ARs following chronic morphine treatment is not due to
quantitative changes at the level of L2-ARs and Gs.
One of the determinants that stabilise the activated receptor
conformation in a native membrane environment is the extent
of basal receptor/G protein precoupling [13,25]. Thus, uncou-
pling of L2-ARs from their associated Gs proteins, as indi-
cated by our radioligand binding studies, might provide a
plausible mechanism for the loss of spontaneous L2-AR activ-
ity. However, there are several objections that argue against
such a mechanism. Most importantly, disruption of receptor/
G protein coupling, e.g. by agonist-mediated phosphorylation,
is usually accompanied by desensitisation of receptor function
[26]. However, stimulatory PGE1 receptors in chronically
morphine treated NG108-15 wild-type cells remained fully
functional following agonist activation [8]. Moreover, ago-
nist-induced desensitisation of L2-ARs in Sf9 cells has been
reported to even increase the potency of inverse agonists to
attenuate basal AC activity [27]. Thus, the loss of spontane-
ously active L2-ARs as observed in chronically morphine-
treated NGL20 cells appears to be mediated by a regulatory
mechanism other than involved in receptor desensitisation.
Recent studies indicated that signal transduction compo-
nents are localised within highly organised membrane com-
partments that bring in speci¢city in transmembrane signal-
ling [28,29]. This is best illustrated with stimulatory receptors
that display high speci¢city in AC stimulation, although they
all utilise the same G protein species for transduction [30].
Given the fact that in NG108-15 cells the amount of Gs is
in far excess over the number of stimulatory receptors [20],
there could be some factors that control the assignment of a
particular receptor to its own G protein pool within the plas-
ma membrane [20,30]. To test whether chronic morphine
treatment possibly interferes with such a mechanism, the in-
teraction of two stimulatory receptors, i.e. PGE1 and L2-ARs,
at the level of Gs was examined by evaluating regulation
of high-a⁄nity [3H]PGE1 binding following activation of
L2-ARs. Increasing concentrations of isoproterenol (1 WM)
dose-dependently (IC50 = 6.5 þ 4 nM) decreased high-a⁄nity
[3H]PGE1 binding to membranes from naive NGL20 cells to
a maximal extent of 33.8 þ 6% (mean values þ S.D.; n = 5),
and this e¡ect was blocked by propranolol. The inverse L2-
AR agonist ICI-118,551 had no reciprocal e¡ect, indicating
that inactivation of spontaneously active L2-ARs does not
increase the availability of PGE1 receptors for Gs. Chronic
morphine treatment failed to a¡ect the overall amount of
GTPQS-sensitive PGE1 receptors in this cell clone (172.2 þ 28
vs. 193.6 þ 37 fmol/mg membrane protein for control and
chronically morphine treated cells, respectively; mean val-
ues þ S.D.; n = 7). However, it signi¢cantly increased the max-
imum capacity of isoproterenol to down-regulate high-a⁄nity
PGE1 receptors by roughly 80% (Fig. 5). These results indi-
cate that chronic morphine treatment somehow increases the
functional interaction between both receptor species at the
level of Gs. One possible explanation for this ¢nding could
be that the pool of Gs assigned to each receptor species be-
comes limited during the state of tolerance/dependence. As in
NG108-15 wild-type cells the number of Gs is in far excess
over the number of receptors [31], limitation in the functional
access of stimulatory receptors for Gs might explain the loss
of spontaneous L2-AR activity without a¡ecting parameters of
receptor-stimulated AC activity in membranes from chroni-
cally morphine-treated NGL20 cells.
In conclusion, the present study demonstrates that in stably
transfected NG108-15 cells chronic morphine treatment re-
duces the number of spontaneously active L2-ARs. Thus, the
relative increase in basal AC activity due to the development
of opioid tolerance/dependence appears to originate from
post-receptor mechanisms that directly up-regulate e¡ector
activity rather than from an increased stimulatory activity.
As stimulatory receptors remain fully functional following
chronic morphine treatment, such a direct increase in AC
activity might explain the phenomenon of an increased sensi-
tivity towards excitatory receptor ligands as observed during
the state of opioid tolerance/dependence.
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